Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockView Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Jubilant Pharmova Ltd (JUBLPHARMA) is currently trading at 1,018.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jubilant Pharmova is an integrated global pharmaceutical and life‑sciences company operating radiopharmaceuticals, radiopharmacies, allergy immunotherapy, CDMO sterile injectables, CRDMO drug discovery and APIs, generics and proprietary novel oncology drugs, with six FDA‑approved manufacturing sites across North America, India and Europe and a network of radiopharmacies concentrated in the United States. The business mix is highly dollarized and US‑centric: approximately 94% of revenues are USD denominated and ~81% of revenues derive from the USA, making Jubilant Pharmova’s commercial performance tightly linked to North American demand, reimbursement dynamics, and regulatory developments while insulating it from US tariff risk through significant Canadian origin share. Radiopharma and specialty services drive margin and growth: Radiopharmaceuticals and radiopharmacy combined with CDMO and CRDMO represent the majority of revenues, with Ruby‑Fill® market leadership in cardiac PET, a 45‑site radiopharmacy network (second largest in the US), and planned PET pharmacy expansion that should materially lift higher‑margin PET revenues. Material capacity and product launches are front and center for growth: the company is doubling Spokane sterile injectable capacity via Lines 3 and 4, building a new isolator Line 5 in Montreal, expanding PET radiopharmacies from 3 to 9, and expects multiple PET/SPECT and a potential MIBG NDA timeline through 2026–27 to unlock incremental high‑margin revenue. Financial targets and discipline are explicit: Vision 2030 targets double revenue to ~Rs.13,500 crore, EBITDA margins of 23–25%, zero net debt and high‑teens RoCE, supported by disclosed capex programs, internal funding and concessional loans, showing management’s clear financial ambition and measurable KPIs to track execution.
Over the past 52 weeks, Jubilant Pharmova Ltd has traded between a low of ₹783.75 and a high of ₹1,183.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jubilant Pharmova Ltd has a market capitalization of approximately 16,329.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jubilant Pharmova Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 46.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,329.84 Cr, Jubilant Pharmova Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jubilant Pharmova Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jubilant Pharmova Ltd is 46.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Jubilant Pharmova said its subsidiary Jubilant Generics received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet.
The USFDA concluded an inspection on June 17, 2026 and issued eight observations, according to Jubilant Pharmova’s disclosure.
They cited near-term impact risks from remediation or shutdown at the Montreal facility in Canada, SPECT product supply shortages, and higher depreciation.
Reports cited a consolidated net profit of ₹151.3 crore in Q4 FY25, while another market report pegged it at ₹153.60 crore, versus a loss in Q4 FY24.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1383.05 | 17,006 Cr | 28.20 | 5.10 | 0.36 | 16.94 | 22.33 | 15.14 | ||
6776.85 | 16,963 Cr | 100.01 | 19.44 | 0.53 | 21.49 | 25.53 | 8.53 | ||
441.55 | 16,834 Cr | 287.62 | 4.30 | 0.00 | 5.05 | 5.47 | 1.02 | ||
1025.65 | 16,330 Cr | 46.47 | 2.30 | 0.49 | 5.62 | 6.41 | 2.26 | ||
810.50 | 15,964 Cr | 23.15 | 2.81 | 1.48 | 11.89 | 10.81 | 7.87 | ||
1510.00 | 15,762 Cr | 57.76 | 7.81 | 0.50 | 12.94 | 17.08 | 12.21 | ||
329.00 | 14,877 Cr | 28.54 | 4.92 | 0.27 | 13.82 | 17.37 | 13.50 | ||
| Median: 7 Co. | — | 1025.65 | 16,330 Cr | 46.47 | 4.92 | 0.49 | 12.94 | 17.08 | 8.53 |
Bearish
7
Neutral
3
Bullish
4
Bearish
10
Neutral
3
Bullish
33
Bearish
3
Neutral
0
Bullish
29
Bearish
7
Neutral
3
Bullish
4
Bearish
7
Neutral
3
Bullish
4
Bearish
3
Neutral
0
Bullish
29
Bearish
3
Neutral
0
Bullish
29
Bearish
3
Neutral
0
Bullish
29
Jubilant Pharmova is an integrated global pharmaceutical and life‑sciences company operating radiopharmaceuticals, radiopharmacies, allergy immunotherapy, CDMO sterile injectables, CRDMO drug discovery and APIs, generics and proprietary novel oncology drugs, with six FDA‑approved manufacturing sites across North America, India and Europe and a network of radiopharmacies concentrated in the United States.
The business mix is highly dollarized and US‑centric: approximately 94% of revenues are USD denominated and ~81% of revenues derive from the USA, making Jubilant Pharmova’s commercial performance tightly linked to North American demand, reimbursement dynamics, and regulatory developments while insulating it from US tariff risk through significant Canadian origin share.
Radiopharma and specialty services drive margin and growth: Radiopharmaceuticals and radiopharmacy combined with CDMO and CRDMO represent the majority of revenues, with Ruby‑Fill® market leadership in cardiac PET, a 45‑site radiopharmacy network (second largest in the US), and planned PET pharmacy expansion that should materially lift higher‑margin PET revenues.
Material capacity and product launches are front and center for growth: the company is doubling Spokane sterile injectable capacity via Lines 3 and 4, building a new isolator Line 5 in Montreal, expanding PET radiopharmacies from 3 to 9, and expects multiple PET/SPECT and a potential MIBG NDA timeline through 2026–27 to unlock incremental high‑margin revenue.
Financial targets and discipline are explicit: Vision 2030 targets double revenue to ~Rs.13,500 crore, EBITDA margins of 23–25%, zero net debt and high‑teens RoCE, supported by disclosed capex programs, internal funding and concessional loans, showing management’s clear financial ambition and measurable KPIs to track execution.
Pharmaceuticals & Biotechnology
Pharmaceuticals
16,229 Cr
Low Risk
46.2
37.4
0.9
2.3
1,183.90
783.75
Sales CAGR
Profit CAGR
ROE
ROCE
